Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor
US9730926B2 · kind B2 · utility
3Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 20, 2015 |
| Grant date | Aug 15, 2017 |
| Priority date | — |
| Expiry date | Jan 20, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical composition including a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor and a method of preventing and/or treating cancer including co-administering a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.